Patent Invalidation in Vancouver.

A patent invalidation Vancouver strategy starts with a jurisdictional fact that surprises many US and European litigants: the Canadian Intellectual Property Office grants patents, but it cannot cancel them. A granted patent is struck down by the Federal Court, which holds national jurisdiction over validity, through an impeachment action under section 60 of the Patent Act. Provincial superior courts in British Columbia can hear infringement, yet validity is effectively Federal Court territory. Vancouver’s economy — hydrogen fuel cells and cleantech, life sciences, software and gaming, and mining technology — files heavily on both sides of the border, so cross-border US patent families matter. PerspireIP builds invalidity-grade prior-art searches for the defendants, generics and competitors who must defeat a Canadian patent on the merits.

Why patent invalidation Vancouver runs through the Federal Court

In the United States a challenger can file an inter partes review at the PTAB; in Canada, the office that grants a patent does not undo it. Under section 60 of the Patent Act, a patent or any claim in it may be declared invalid or void by the Federal Court, at the instance of the Attorney General of Canada or of any interested person. The Federal Court sits across the country and its judgment on validity has national effect, so a single action can clear a patent everywhere in Canada, Vancouver included.

“Interested person” is read broadly. It covers anyone who might have the patent asserted against them — a company making or selling a product in British Columbia that arguably falls within the claims. The burden sits on the challenger to prove invalidity, and section 60(3) generally requires security for costs before the statement of claim issues, though a defendant already sued for infringement can seek a declaration without posting it.

The provincial split matters in practice. The Supreme Court of British Columbia can hear an infringement claim, but a validity attack belongs in the Federal Court, where discovery, expert evidence and a full trial on the prior art are available. That is why we tie every search to the forum: the decisive reference has to survive cross-examination, not just a keyword match.

CIPO re-examination: a faster, narrower route

Not every challenge needs a full impeachment trial. The Patent Act also lets any person request re-examination of any claim in an issued patent by filing prior art with the Commissioner of Patents. A re-examination board decides, usually within three months, whether the art raises a substantial new question of patentability; if it does, the patentee may respond and amend claims without broadening them, and the board rules on patentability.

The trade-offs are real. Re-examination is quick and inexpensive, but it is limited: the request must rest on patents, published applications and printed publications, so grounds like prior use, prior sale, inutility and insufficient disclosure cannot be raised there. A third party also has no further say once the process starts and no right of appeal from a “no substantial question” finding. It has been used sparingly since 1989.

For a Vancouver challenger the two routes are complementary. A tightly built printed-publication dossier can drive a cheap re-examination against the strongest claims, and that same art can later anchor a Federal Court impeachment action if the patent survives. Choosing the door — and which references belong behind it — is part of what we scope before pulling a single document.

The end of the promise doctrine and modern utility

Utility law in Canada changed decisively in 2017. In AstraZeneca Canada Inc. v. Apotex Inc., 2017 SCC 36, the Supreme Court of Canada struck down the “promise doctrine,” which had allowed a patent to be invalidated if any promised use stated in the disclosure was not demonstrated or soundly predicted. For a decade that doctrine had sunk numerous patents, pharmaceutical patents most of all, because they often name medical uses without clinical data in the specification.

The Court held that the promise doctrine was not the right test for utility under section 2 of the Patent Act, because it wrongly conflated utility with sufficiency — two separate inquiries. Instead, a mere scintilla of utility will do: a single use related to the subject matter of the claim, established by demonstration or sound prediction as of the filing date, satisfies the requirement.

The practical lesson for anyone attacking a Canadian patent is to stop leaning on inutility. Post-AstraZeneca, a bare utility argument rarely wins on its own. The stronger, more durable attacks are anticipation and obviousness built on prior art the examiner never retrieved — which is exactly where an invalidity search earns its keep.

Grounds under the Patent Act and the grace period

A Federal Court impeachment can raise any ground of invalidity. The core statutory tests are familiar to patent litigators everywhere, but each turns on Canadian dates and Canadian evidence:

• Anticipation — lack of novelty under section 28.2, measured against everything made available to the public before the claim date
• Obviousness under section 28.3, judged from the skilled person’s perspective as of the claim date
• Inutility under section 2, now only a scintilla after AstraZeneca 2017 SCC 36
• Insufficiency under section 27, where the specification fails to enable a skilled person to work the invention
• Overbreadth — claims broader than the invention made or disclosed
• Wrong owner, or subject matter excluded from patentability

Canada is a first-to-file system for applications filed after 1989, and it offers a one-year grace period for disclosures traceable to the applicant. Under sections 28.2 and 28.3, an inventor’s own pre-filing disclosure inside the twelve months before the Canadian filing date does not, by itself, anticipate or render the claim obvious. Fixing the operative claim date, and proving a reference was genuinely public before it, is therefore the evidentiary heart of every case — not the keyword hit.

PM(NOC) pharma litigation in the Federal Court

Much of Canada’s patent litigation is pharmaceutical, and it runs on its own track. The Patented Medicines (Notice of Compliance) Regulations — the PM(NOC) Regulations — link a generic manufacturer’s Health Canada approval to the innovator’s listed patents. When a generic serves a notice of allegation challenging those patents, the innovator can start an action in the Federal Court, and validity is squarely in play.

These proceedings follow a compressed timetable and slightly different rules from an ordinary patent action, but they are full actions with discovery and expert evidence, not the old summary applications. For a generic entering the British Columbia market, the invalidity case is built the same way an impeachment is: claim by claim, against anticipation, obviousness, insufficiency and overbreadth, on the prior art the examiner missed.

Subject matter is a live front, too. CIPO’s evolving guidance on patentable subject matter for diagnostics, medical-use and biotechnology claims has sharpened both prosecution scrutiny and the corresponding invalidity attacks in litigation. We tune the search to the claim type — small molecule, formulation, dosage regimen or diagnostic method — because each invalidates on different evidence.

Vancouver’s industries and where the decisive prior art lives

Vancouver is Canada’s third-largest technology hub, and its patent docket mirrors that mix. British Columbia is home to more than a quarter of Canada’s clean-technology companies, anchored by hydrogen fuel-cell pioneers such as Ballard Power Systems, alongside life sciences, software and video-game studios, and a deep bench of mining and resource-tech firms. Many of these companies file first in the United States, so the asserted right often sits in a cross-border patent family.

Those are chemistry, electrochemistry, biotech, mechanical and software technologies, and they invalidate on very different evidence. The reference that sinks a fuel-cell membrane, a gene-sequence, a game-engine or an ore-processing claim is rarely the headline patent a first-pass keyword search surfaces. It is usually buried in the literature the examiner never reached.

• Fuel-cell, electrolyzer and cleantech literature, membrane datasheets and older energy patent families
• Biotech and life-sciences sequence databases, clinical publications and conference proceedings
• Software and game-engine art — open-source repositories, developer documentation and technical blogs
• Mining and resource-technology handbooks, standards and equipment manuals
• US and PCT co-pending families and file histories from the cross-border filing patterns typical of BC innovators
• Foreign-language disclosures and theses an examiner is unlikely to have retrieved

The other half of the job is proof of date. A reference only counts if it was public before the operative claim date. We treat public-availability dating as evidence — capturing archive timestamps, publication records and library holdings that a Federal Court will accept without a side dispute over authenticity.

How PerspireIP builds a patent invalidation Vancouver case

Every engagement follows the same disciplined path. We chart the asserted claims element by element, fix the claim date that governs each one, and search against that date rather than the grant date printed on the cover. For fuel-cell, biotech, software and mining subject matter we run patent and deep non-patent-literature retrieval in parallel and pull the US and PCT family art that cross-border prosecution often leaves on the table.

• Claim charts mapped to the grounds a Federal Court applies — anticipation, obviousness, utility, insufficiency and overbreadth
• Parallel patent and non-patent-literature searching tuned to cleantech, life-sciences, software and mining claims
• A read on whether re-examination at CIPO or an impeachment action is the sharper route for the strongest claims
• PM(NOC)-ready prior art for pharmaceutical challenges on the Federal Court timetable
• Public-availability dating evidenced for every reference, tied to the operative claim date

We work alongside your Canadian patent litigators as a specialist search partner, deliver to court and re-examination deadlines, and keep every engagement confidential. Whether you are a Vancouver manufacturer facing an infringement suit, a generic clearing a product for the Canadian market, or litigation counsel coordinating an impeachment defence, we scale to fit. Send us the patent number and your key dates, and we will scope a patent invalidation Vancouver project within one business day.

IP Landscape & Resources in Vancouver

Key intellectual-property authorities and venues relevant to Vancouver:

• Canadian Intellectual Property Office (CIPO) — the federal agency that examines and grants Canadian patents and administers re-examination by the Commissioner of Patents
• Federal Court of Canada — the court with national jurisdiction over patent validity, which hears impeachment actions under section 60 and PM(NOC) proceedings
• Patent Act, RSC 1985, c. P-4 (Justice Laws Canada) — the statute governing Canadian patents, including section 60 impeachment and the novelty and obviousness grounds
• AstraZeneca Canada Inc. v. Apotex Inc., 2017 SCC 36 (CanLII) — the Supreme Court of Canada decision abolishing the promise doctrine and setting the modern scintilla standard for utility

Request a Patent Invalidation Search in Vancouver

Explore related PerspireIP services: Patent Invalidation · Prior Art Litigation Search · Patent Infringement Analysis.

Frequently Asked Questions